Trial
NCT02118584
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Etrolizumab
Why stopped
The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-23